The Global Alzheimer’s Agitation Treatment Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.8 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period (2023-2030). With over 55 million people worldwide affected by Alzheimer’s disease and related dementias, pharmaceutical companies are accelerating development of targeted therapies to manage agitation – one of the most distressing neuropsychiatric symptoms that affects up to 70% of dementia patients.
As regulatory pathways evolve and new pharmacological mechanisms emerge, this analysis profiles the Top 10 Companies in the Alzheimer’s Agitation Treatment Market—a mix of neuroscience powerhouses and emerging biotechs developing innovative solutions for this critical unmet medical need.
🔟 1. Eisai Co., Ltd.
Headquarters: Tokyo, Japan
Key Offering: Aricept (Donepezil), Lemborexant (Dayvigo)
Eisai maintains market leadership with Aricept, the world’s most prescribed Alzheimer’s medication. The company’s neurology division is developing novel agitation-specific formulations and exploring digital monitoring solutions for behavioral symptoms.
Clinical Pipeline:
- Phase II investigation of serotonin receptor modulators for agitation
- Collaboration with digital health firms for AI-driven symptom tracking
- Modified-release formulations in development for geriatric populations
Download FREE Sample Report: Alzheimer’s Agitation Treatment Market – View in Detailed Research Report
9️⃣ 2. Biogen Inc.
Headquarters: Cambridge, Massachusetts, USA
Key Offering: Aduhelm (aducanumab), Leqembi (lecanemab)
While focused on disease-modifying therapies, Biogen dedicates significant resources to symptomatic treatments. The company is investigating glutamate modulation and other novel mechanisms for agitation management.
Research Focus:
- NMDA receptor-targeted compounds in Phase II trials
- Digital biomarkers for tracking symptom progression
8️⃣ 3. H. Lundbeck A/S
Headquarters: Valby, Denmark
Key Offering: Rexulti (brexpiprazole)
Lundbeck specializes in CNS disorders and markets Rexulti, FDA-approved for agitation associated with Alzheimer’s dementia. The company is advancing next-generation serotonergic compounds with improved safety profiles.
Innovation Pipeline:
- Novel 5-HT2A antagonists with reduced metabolic side effects
- Transdermal delivery systems in development
7️⃣ 4. Otsuka Pharmaceutical
Headquarters: Tokyo, Japan
Key Offering: Abilify (aripiprazole)
Otsuka’s neuroscience portfolio includes antipsychotics used off-label for agitation management. The company collaborates with global researchers to develop targeted symptom-specific therapies.
Therapeutic Development:
- Dopamine stabilizers with reduced extrapyramidal effects
- Personalized medicine approaches using genetic biomarkers
6️⃣ 5. Eli Lilly and Company
Headquarters: Indianapolis, Indiana, USA
Key Offering: Zyprexa (olanzapine)
Lilly maintains a strong position in neuropsychiatry with multiple compounds in development for behavioral symptoms. The company’s substantial R&D budget prioritizes innovative CNS therapies.
Clinical Programs:
- Novel mechanism compounds targeting agitation neurobiology
- Integrated digital therapeutics platforms
5️⃣ 6. Novartis AG
Headquarters: Basel, Switzerland
Key Offering: Exelon (rivastigmine)
Novartis develops comprehensive Alzheimer’s solutions through its neuroscience division, including transdermal delivery systems for symptom management and novel pharmacological approaches.
Strategic Initiatives:
- Advanced cholinesterase inhibitor formulations
- Global clinical trial networks for agitation treatments
Download FREE Sample Report: Alzheimer’s Agitation Treatment Market – View in Detailed Research Report
4️⃣ 7. Johnson & Johnson
Headquarters: New Brunswick, New Jersey, USA
Key Offering: Risperdal (risperidone)
J&J’s Janssen division maintains a robust neuroscience pipeline with multiple compounds in development for dementia-related behavioral symptoms, combining pharmacological and digital therapeutic approaches.
Innovation Strategy:
- Precision psychiatry applications for personalized treatment
- AI-powered clinical decision support systems
3️⃣ 8. AstraZeneca
Headquarters: Cambridge, United Kingdom
Key Offering: Seroquel (quetiapine)
While narrowing its CNS focus, AstraZeneca continues agitation research through collaborations and retains key neuropsychiatric assets. The company explores optimized formulations for elderly patients.
Development Focus:
- Extended-release antipsychotic formulations
- Neuroprotective combination therapies
2️⃣ 9. Pfizer Inc.
Headquarters: New York, New York, USA
Key Offering: Neurodegenerative disease research platforms
Pfizer maintains Alzheimer’s research initiatives including agitation management, leveraging its extensive CNS expertise and biomarker discovery capabilities.
Research Directions:
- Novel MOA compounds in preclinical evaluation
- Digital phenotyping for symptom monitoring
1️⃣ 10. Axsome Therapeutics
Headquarters: New York, New York, USA
Key Offering: AXS-05 (dextromethorphan-bupropion)
This innovative biotech’s NMDA receptor modulator demonstrated significant agitation reduction in Phase III trials. Axsome represents the vanguard of targeted neurological symptom therapies.
Differentiation:
- First multi-mechanism approach approved for agitation
- Rapid clinical translation program
Get Full Report Here: Alzheimer’s Agitation Treatment Market – View in Detailed Research Report
🧠 Market Outlook: The Future of Agitation Management
The Alzheimer’s agitation treatment landscape is undergoing significant transformation, with targeted therapies and integrated care models replacing traditional off-label approaches. Emerging treatments aim to improve both efficacy and safety profiles for vulnerable elderly populations.
📈 Key Market Trends:
- Shift from broad-acting antipsychotics to mechanism-specific therapies
- Growing regulatory pathways for agitation-specific indications
- Increased adoption of digital monitoring solutions
- Expanding reimbursement for non-pharmacological interventions
Get Full Report Here: Alzheimer’s Agitation Treatment Market – View in Detailed Research Report
The profiled companies are driving critical innovations to address one of Alzheimer’s most challenging aspects—developing effective, well-tolerated treatments for agitation that preserve patient dignity and quality of life while supporting caregivers.